MEDGENOME

Company Overview

MedGenome Inc., founded in 2013, is developing and marketing diagnostics tests for immune-oncology, diabetes ophthalmology, cardiology, and other rare diseases.

The company has an NGS facility in California that includes Illumina’s NovaSeq, HiSeq X, HiSeq 2500 and MiSeq.

MedGenome markets a proprietary cancer immunotherapy solution, OncoPept, which combines tumor-derived genomic and transcriptomic data to map the molecular features of the tumor and predict personalized cancer immunotherapy combinations with neoantigen vaccines for therapy.

In November 2021, the company, which is a leading genomics research and diagnostics company in South Asia, announced a strategic partnership with Emmes. Emmes, a global full-service clinical research organization, is dedicated to advancing public health and biopharmaceutical innovation. The collaboration aims to accelerate breakthrough treatments utilizing human genomics for rare disease patients, particularly in India and South Asia.

Company's Business Segments

• CLARIA : Non-invasive prenatal screening test (NIPT), Carrier Screening, PGT-A/PGT-M, SR, Recurrent Pregnancy Loss Test, Rhesus D Track, Molecular Cytogenetics, Maternal Serum Screening, KaryoSeq.
• ACTIA : ExomeMAX, Whole Exome, Rapid Exome Analysis, Trio Exome, Clinical Exome, Chromosomal Microarray, Neuro Genetics, FSHD1, Newborn Screening, Nephro Genetics, Metabolic Genetics, Cardio Genetics, Endocrine Genetics, Ocular Genetics, ENT Genetics, Polygenic Risk Score for CAD.
• PRIMA : Liquid Biopsy, TumorTrack Advance, Thyrotrack, LungTrack Advance, BRCA1 and BRCA2 Gene Test, HLA Typing, Tumor Mutation Burden, Molecular testing for Solid Tumors, Molecular testing for Hematological Malignancies, clonoSEQ NGS MRD, Thalassemia Mutation Testing, Immunophenotyping by Flowcytometry.
• MICRA : SPIT SEQ, TB Diagnostics Solution, Gastrointestinal Infections, SES for CNS Infections, SES for Systemic Infections, SES for Eye Infections, COVID-19 (SARS-CoV2) RT-PCR Test.